BlackRock, Inc. 13D and 13G filings for Celldex Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-04-17 09:35 am Sale | 2025-03-31 | 13G | Celldex Therapeutics, Inc. CLDX | BlackRock Inc. BLK | 4,819,293 7.300% | -661,377 (-12.07%) | Filing |
| 2025-02-05 1:23 pm Purchase | 2024-12-31 | 13G | Celldex Therapeutics, Inc. CLDX | BlackRock Inc. BLK | 5,480,670 8.300% | 1,804,978 (+49.11%) | Filing |
| 2024-01-26 5:25 pm Purchase | 2023-12-31 | 13G | Celldex Therapeutics, Inc. CLDX | BlackRock Inc. BLK | 3,675,692 6.700% | 450,976 (+13.98%) | Filing |
| 2023-01-31 5:52 pm Purchase | 2022-12-31 | 13G | Celldex Therapeutics, Inc. CLDX | BlackRock Inc. BLK | 3,224,716 6.800% | 123,686 (+3.99%) | Filing |
| 2022-02-04 4:12 pm Purchase | 2021-12-31 | 13G | Celldex Therapeutics, Inc. CLDX | BlackRock Inc. BLK | 3,101,030 6.600% | 3,101,030 (New Position) | Filing |